Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Granules India receives 1 observation from USFDA for Chantilly facility
Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated
